Cargando…
Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC)
BACKGROUND: Although mammography screening is recommended in most European countries, the balance between the benefits and harms of different screening intervals is still a matter of debate. This review informed the European Commission Initiative on Breast Cancer (BC) recommendations. METHODS: We se...
Autores principales: | Canelo-Aybar, Carlos, Posso, Margarita, Montero, Nadia, Solà, Ivan, Saz-Parkinson, Zuleika, Duffy, Stephen W., Follmann, Markus, Gräwingholt, Axel, Giorgi Rossi, Paolo, Alonso-Coello, Pablo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854566/ https://www.ncbi.nlm.nih.gov/pubmed/34837076 http://dx.doi.org/10.1038/s41416-021-01521-8 |
Ejemplares similares
-
Digital breast tomosynthesis compared to diagnostic mammographic projections (including magnification) among women recalled at screening mammography: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC)
por: Canelo‐Aybar, Carlos, et al.
Publicado: (2021) -
Preoperative breast magnetic resonance imaging in patients with ductal carcinoma in situ: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC)
por: Canelo-Aybar, Carlos, et al.
Publicado: (2021) -
Correction to: Preoperative breast magnetic resonance imaging in patients with ductal carcinoma in situ: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC)
por: Canelo-Aybar, Carlos, et al.
Publicado: (2022) -
Biennials, Triennials, and Documenta
por: Gardner, Anthony
Publicado: (2016) -
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative
por: Giorgi Rossi, Paolo, et al.
Publicado: (2021)